Moreover, the combined application of oncolytic adenovirus XVir-N-31, driven by YB-1, with CDK4/6 inhibitors, is observed to facilitate the maturation of monocyte-derived DCs, thus increasing their capacity in activating tumor antigen-specific T cells (Schober et al., 2023). Here, CDK4 is linked to neoplasm.